UCSF Fresno Department of Surgery, 2823 Fresno St., 1st Floor Surgery, Fresno, CA, USA, 93721.
Am J Surg. 2020 Dec;220(6):1503-1505. doi: 10.1016/j.amjsurg.2020.08.042. Epub 2020 Sep 9.
Levetiracetam and phenytoin are comparable for acute posttraumatic seizure(PTS) prophylaxis. Levetiracetam-induced hyponatremia has been reported in non-trauma patients. We studied hyponatremia in posttraumatic intracranial hemorrhage(ICH) patients receiving either drug.
Retrospective review of patients with ICH receiving PTS prophylaxis was performed. Patients were categorized by degree of sodium nadir: normal, mild, moderate, or severe, and analyzed by levetiracetam versus phenytoin. Patients were matched 2:1 regarding age and injury severity score(ISS). Incidence and treatment for hyponatremia was examined.
1735 ICH patients received PTS prophylaxis over an 8-year period. After exclusions and matching, there were 282 phenytoin and 564 levetiracetam patients. Age, ISS and initial sodium were comparable between the matched cohorts. There was no clinically significant difference in the rate or degree of hyponatremia. Treatment was more common in levetiracetam patients.
There was a small but clinically insignificant difference in the incidence of hyponatremia in traumatic ICH patients receiving levetiracetam vs. phenytoin for PTS prophylaxis. There was an increased rate of intervention for hyponatremia in the levetiracetam group, possibly due to a coincidental preventive paradigm shift.
左乙拉西坦和苯妥英钠在急性创伤后癫痫(PTS)预防方面效果相当。已有非创伤患者使用左乙拉西坦引起低钠血症的报道。我们研究了接受这两种药物之一治疗的创伤性颅内出血(ICH)患者的低钠血症情况。
对接受 PTS 预防的 ICH 患者进行回顾性研究。根据血清钠最低值的程度将患者分为正常、轻度、中度或重度,并对左乙拉西坦和苯妥英钠进行分析。根据年龄和损伤严重程度评分(ISS)将患者 2:1 匹配。检查低钠血症的发生率和治疗情况。
8 年间,1735 例 ICH 患者接受 PTS 预防。排除和匹配后,有 282 例苯妥英钠和 564 例左乙拉西坦患者。匹配队列之间的年龄、ISS 和初始血清钠相似。低钠血症的发生率或严重程度无临床显著差异。左乙拉西坦组的治疗更为常见。
在接受 PTS 预防的创伤性 ICH 患者中,左乙拉西坦与苯妥英钠相比,低钠血症的发生率虽小,但无临床意义。左乙拉西坦组低钠血症干预率增加,可能是由于预防范式的巧合转变。